Patrick Y. Yang, PhD
Chairman and Co-Founder
Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his BS in Engineering from National Chiaotung University (Taiwan), his MS from the University of Cincinnati, and his PhD in Engineering from The Ohio State University.
Sonny Hsiao, PhD
Chief Executive Officer, President and Co-Founder
Dr. Hsiao is the Chief Executive Officer, President and Co-Founder at Acepodia. Dr. Hsiao has extensive research experiences in immune cell therapies, which lead to the discovery of components of ACC™ (Antibody-Cell Conjugation) technology to the invention of the novel cellular immunotherapy, ACE™ (Antibody-Cell Conjugation Effector cells). Dr. Hsiao earned his BS in Chemistry from National Taiwan University, and his PhD in Chemistry and Molecular Cell Biology from the University of California, Berkeley.
Joseph S. McCracken, DVM, MS
Head of Business Development
Dr. Joe McCracken advises companies on the design and implementation of corporate strategy and business development; and serves on the Boards of Alkahest, Inc., EdiGENE Corporation, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously VP and Global Head of BD & Licensing for Roche, where he was responsible for Roche’s global licensing activities. From October 2009 until July 2011 he was General Manager, Roche Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche, he held the position of VP, Business Development at Genentech for more than 10 years, and held positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a BS in Microbiology, a MS in Pharmacology and a DVM from The Ohio State University.
Bill Mackin, PhD, RAC
Head of Regulatory Affairs
Bill Mackin, PhD, RAC, is President of WMackin & Associates. As a seasoned drug development and regulatory affairs expert with over 25 years in the biopharmaceutical industry, he has held senior leadership positions in regulatory and manufacturing functions within a number of biopharmaceutical companies and consultant agencies, including Aptuit Consulting. Dr. Mackin received his BS in Biology and Microbiology from Univerisity of Illinois at Urbana-Champaign, and PhD in Microbiology and Immunology from University of Illinois at Chicago. Dr. Mackin was a post-doctoral fellow at University of Connecticut Health Center.
Janet Pan, MS
Director of Clinical Operations
Janet Pan is the Director of Clinical Operations at Acepodia, Taiwan. Prior to joining Acepodia, her experiences were in clinical research coordination and management, with work experience from University of California San Francisco (UCSF, Obstetrics and Gynecology) and Stanford Medicine (Cancer Clinical Trials Office). She also has data management experience from UCSF and Clinipace. Janet earned her BS in Biochemistry from University of Washington, and Master of Public Health (MPH) with subspecialty in Epidemiology and Biostatistics from University of California, Berkeley.
David Lai, MS
Director of Operations
David Lai is the Director of Operations at Acepodia Taiwan. He served in AstraZeneca Taiwan for several years, responsible for sales and marketing of therapeutic drugs, specific to diabetes and cardiovascular disease. Prior to AstraZeneca, David Lai was the researcher at the Development Center of Biotechnology (DCB), and in charge of setting up phage-display system for therapeutic antibody selection and rodent antibody humanization platform. He earned his BS in Forestry from National Taiwan University and MS in Biochemistry and Molecular Biology from National Yang-Ming University, Taiwan.